Member Info for Boonco

I didn't think there would be but seeing as fortnefvrsbrve tried to get everyone excited I figured I should post a link that works.

Merck oncology investor event held yesterday. No idea if anything relevant as I'm too busy to watch it.

https://www.merck.com/events/merck-co-inc-oncology-event-at-asco-2022/

Good interview.

AN didn't seem remotely angry to me he was just being honest and straightforward about the type of investor that should be interested in the company. Besides, it's not like it's the first time he's stated that they have zero interest in trying to make a quick buck and that it's a long term play. He's previously said that Morgan Stanley are supportive for the long haul because they can see the vast uncapped long term potential.

He can count on my continued support.

I think that for Oxford finance news to by itself cause the share price to rise to any significant degree it would need to be a renegotiated deal and significantly increased next tranche. As it is the next tranche as currently agreed will be around £6 million, enough to cover estimated operating costs for around 3 months only. Any breathing room is obviously welcome but it's hardly an extensive platform running well into next year. At most it takes the company through to end of Q1 2013 only and that's only if current cash is enough to cover all of Q4 this year.

Sangi, from my perspective AN is right to speak poorly of the NHS administration. There are lot of good individuals in the NHS but after working with it commercially for a decade across medtech/biotech I have no qualms saying that as an organisation it truly is dysfunctional and hugely frustrating to deal with.

Keytruda at #4 with only one of the three drugs above it not being related to covid, Abbvie's Humira.

https://www.fiercepharma.com/special-reports/top-20-drugs-worldwide-sales-2021

Taking a company public via IPO rather than a traditional direct listing is daft.

If you're interested in the topic have a read of this piece by Bill Gurley, one of silicon valleys most respected VC's. It's not a quick 2 minute read but it lays out precisely why the IPO really isn't anything more than a great wealth transfer tool.

https://abovethecrowd.com/2021/06/03/customers-love-free-stuff-but-thats-not-your-problem/

I've always expected them to at least dual list at somepoint. As you say, the UK is just an appalling market for emerging/high growth healthcare companies. It always has been and despite the gov's desires to change that reality it always will be until the requisite institutional knowledge is put in place and the UK investment community from ii's down (public and private) rids itself of addiction to the short term and its pathological aversion to uncertainty and long term thinking.

Dual list to start with at least to keep UK PI's onboard and offer them a time restricted option to convert their aim shares to ADR's at no conversion cost (ADR holding bank would still charge annual admin fee based on quantity of shares held).

Just as silly was starting a thread about a possible placing but in the same post admitting you have no idea about the current bank balance.

Merck have better things to do with their time than try to actively undermine the share price of a partner/investment interest.

https://www.science.org/toc/science/current

Perspectives are open access, reviews are subscription only

Yes, they’ll still need to prove it works for the intended cancer type but they won’t need to do a lot of the work that they had to do to get de novo clearance.

"So the FDA have cleared for metastatic breast cancer. How long before they clear for the next cancer.. and the one after that..

If it works for one type of cancer it must surely work for several, or many more, solid tumours. Do the FDA rule on each one, individually?"

Yes they will, it will be classed as a change of intended use so they'll need to apply for what's known as 510k clearance.

https://www.fda.gov/medical-devices/device-approvals-denials-and-clearances/510k-clearances

Exactly Sangi.

This is the UK though and uk investors generally have a pathological aversion to long-term investing, at least at the institutional level.

At least AN has previously said that the US funds onboard understand the long term opportunity and like him are in it for the long haul.

long term holder here :)

That should put to bed the daft tin foil hat posts I've read on here previously about the fda favouring US companies etc

Same here isas, give it a few years and with the bit of luck every company needs 4D has the potential to be considerably north of £3.74. It unquestionably has the potential to be a £multi billion business it's just a question of whether the pieces will fall into place for it to eventually get there.

It's just a pity the folk who write these articles often make silly but fundamental mistakes like not converting the valuation.

For anyone new to 4D, ignore this passage of the article…

“However, they will be overjoyed if analysts at Ladenburg Thalmann are correct; the US investment bankers have a substantial $37 (£29.94) target price on 4D Pharma shares. That’s a potential 85 times upside should the target price be met.”

The target price is correct for Nasdaq but it's wildly wrong for ordinary shares on aim. 1 share on aim equates to 8 shares on nasdaq i.e. divide £29.94 by 8 and the analyst's target price for aim listed shares is £3.74

Good grief

Near enough to make no difference. One dropped 30% yesterday alone so I topped up.

We could if there was any point or benefit to be gained from moaning, I've got several companies on my watch list down 6%+ today.